Clinical Trial Update: GutHeart: Targeting Gut Microbiota to Treat Heart Failure [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating gut microbiota modulation as a treatment for systolic heart failure; status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systolic Heart Failure

Snippet

Sponsor: Oslo University Hospital | Conditions: Systolic Heart Failure | Phase 2 | Status: UNKNOWN